Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

Third Phase II Trial Initiated by Myriad For Azixa(TM)

TARRYTOWN, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today reported on new clinical advancements for Azixa(TM)* (MPC-6827), a vascular disrupting agent licensed by the Company to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Myriad announced yesterday that it has initiated a third Phase II clinical trial for Azixa in patients with non-small-cell lung cancer that has spread to the brain. The trial is designed to assess Azixa's safety profile and the extent to which it can improve the overall survival of these patients. Two additional Phase II trials for Azixa are underway in primary brain cancer and melanoma that has spread to the brain.

"We are pleased at the clinical advancement Myriad has reported on Azixa, and view it as further evidence of the commercial potential of the compound," stated Jack Talley, President and Chief Executive Officer. "We believe that the study of Azixa in this new indication affords EpiCept with an expanded opportunity to capitalize on the financial benefits associated with our agreement with Myriad, including milestone payments, sublicensing income and potentially future royalties if Azixa continues to progress successfully."

Myriad is responsible for the worldwide development and commercialization of Azixa and any drug candidate that is developed from the series of compounds licensed by EpiCept to Myriad in 2003. The agreement requires that Myriad make future licensing, research and milestone payments to EpiCept, as well as pay a portion of any sublicensing income and pay a royalty on product sales. EpiCept will earn a milestone payment upon the dosing of the first patient in a Phas
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Greifensee, Switzerland (PRWEB) October 01, 2014 ... influence the quality of the final product. However, ... most regulated, regulatory frameworks such as Good Manufacturing ... is the responsibility of the manufacturer to interpret ... ensure consistent weighing performance quality. METTLER TOLEDO experts ...
(Date:10/1/2014)... Today the National Institutes of ... for the Brain Research through Advancing Innovative Neurotechnologies ... and revolutionize new methods of understanding the complexities ... This first round of grants totaling $46 million ... to more than 100 investigators in 15 states ...
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... a well-known optical phenomenon called thin-film interference, a ... the ability to "paint" ultra-thin coatings onto a ... making future, flexible electronic devices, creating advanced solar ... ships and spacecraft with extremely lightweight decorative logos. ... it becomes iridescent, revealing a myriad of colors ...
Breaking Biology Technology:Comply with Weighing-Related Regulations in Pharma Manufacturing 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2
... 2011 Reaction Biology Corporation ("RBC"), a leading ... epigenetics, today announced the rollout of a new ... initial offerings will emphasize the histone methyltransferases (HMTs), ... no previous commercial source. The ...
... Fla., Oct. 24, 2011 GeneLink BioSciences, Inc. ... leading consumer genomics biotech company, today announced that it ... Deloitte,s ranking of 500 of the fastest growing technology, ... North America. GeneLink grew 4,363 percent during the period ...
... Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), ... People,s Republic of China, today announced that it has ... "200 Best Under a Billion" for the year 2011. ... for the year 2009. According to Forbes ...
Cached Biology Technology:Reaction Biology Launches Recombinant Methyltransferase Line 2GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 2GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 3China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 2China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 3
(Date:9/30/2014)... in almost any aquatic environment on Earth, but when ... are pushed to the limit. The amount of time ... for how different species cope in the future, reveals ... Gothenburg, published in the scientific journal Proceedings of ... apace thanks to increasing levels of greenhouse gases in ...
(Date:9/30/2014)... research, involving mice and published in the October 2014 ... , suggests that just because you can do ... team of Italian scientists have found that using marijuana ... immune system. This damage may result in autoimmune diseases ... bowel disease and rheumatoid arthritis in adulthood. , "I ...
(Date:9/30/2014)... with IVF? Here,s some hope: A new research report ... FASEB Journal , explains how scientists developed a ... which induced embryo development in human and mouse eggs ... the sperm cell during fertilization. , "We believe that ... shift in our understanding of human fertilization by providing ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Adolescent exposure to thc may cause immune systems to go up in smoke 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... viruses is also involved in keeping cancer cells alive, researchers ... anti-viral molecule, called TBK-1, was found to be essential for ... a treatment for fighting cancer, the researchers report in today's ... that this mechanism is involved in cancer cell survival, even ...
... to transform into a new life, or into new cells ... in the mechanics - in how a single cell can ... this week in the Proceedings of the National Academy ... human egg. The identification opens the way to understanding these ...
... of different types of nerve cells by neural stem ... much of one kind of cell and too little ... brain malformations. In the October 6 issue of Cell, ... report discovering a new molecular pathway that influences the ...
Cached Biology News:Natural anti-viral enzyme helps keep cancer cells alive, researchers find 2Scientists crack genetic secrets of human egg 2Novel pathway regulates timing of brain cell development 2
...
... from vaccinia virus is a type I ... negative superhelical turns (also called right- and ... product of the reaction is a covalently ... negative superhelical turns. DNA Topoisomerase I does ...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
...
Biology Products: